{"analyses":[{"ciLowerLimit":"76","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"107","groupDescription":"PLD was the Reference treatment and Avelumab + PLD was the Test treatment.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio (Test/Reference, %)","paramValue":"90"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20","value":"2848000"},{"groupId":"OG001","spread":"30","value":"2571000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"AUC336 was defined as area under the concentration time profile from time zero to 336 hours.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG000","title":"Pegylated Liposomal Doxorubicin (PLD)"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK parameter analysis set was defined as a subset of the safety analysis set and included patients who had at least one of the PK parameters of interest for doxorubicin.","reportingStatus":"POSTED","timeFrame":"From predose (0 H) of Cycle 2 Day 1 through 336 hours postdose","title":"Area Under The Concentration Time Profile From Time Zero to 336 Hours (AUC336) For Doxorubicin Following Cycle 2 Day 1 PLD Dose","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}